| pubmed-article:7814893 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C0072980 | lld:lifeskim |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C0443146 | lld:lifeskim |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7814893 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:7814893 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7814893 | pubmed:dateCreated | 1995-2-9 | lld:pubmed |
| pubmed-article:7814893 | pubmed:abstractText | Immunosuppressive drugs currently available for the treatment of autoimmune diseases display a narrow therapeutic window between efficacy and toxic side effects. The use of combinations of drugs that have a synergistic effect may expand this window and reduce the risk of toxicity. We evaluated the combination effect of rapamycin (Rapa) and cyclosporin A (CsA) in an autoimmune disease model of the eye. The dose-effect relationship of Rapa with CsA was measured in vitro on the inhibition of proliferation of retinal S-Ag-primed lymphocytes. A median effect analysis was performed and a combination index (CI) calculated for 50% inhibition of proliferation. Rapa and CsA were markedly synergistic over a wide dose range (lowest CI = 0.31). Calculated dose reduction factors indicated that Rapa could be reduced nine-fold and CsA reduced five-fold when these drugs were used in combination. These reduced doses were tested in vivo for the treatment of experimental autoimmune uveoretinitis (EAU). Twelve of 15 rats treated with CsA, 2 mg/kg/day, developed EAU with a median severity of 2.5. Fourteen of 15 rats treated with Rapa, 0.01 mg/kg/day, developed EAU with a median severity of 3.25. Complete inhibition of EAU was achieved in all 15 animals treated with the combination of Rapa and CsA (combined vs CsA alone, p < 0.0002; combined vs Rapa alone, p < 0.00001). The demonstrated synergistic relationship between Rapa and CsA will allow the use of reduced doses of each drug to achieve a therapeutic effect. The use of lower doses may reduce the toxicity of these drugs for the treatment of autoimmune uveitis. | lld:pubmed |
| pubmed-article:7814893 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7814893 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7814893 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7814893 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7814893 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:7814893 | pubmed:author | pubmed-author:ChanC CCC | lld:pubmed |
| pubmed-article:7814893 | pubmed:author | pubmed-author:MartinD FDF | lld:pubmed |
| pubmed-article:7814893 | pubmed:author | pubmed-author:NussenblattR... | lld:pubmed |
| pubmed-article:7814893 | pubmed:author | pubmed-author:RobergeF GFG | lld:pubmed |
| pubmed-article:7814893 | pubmed:author | pubmed-author:DeBargeL RLR | lld:pubmed |
| pubmed-article:7814893 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7814893 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7814893 | pubmed:volume | 154 | lld:pubmed |
| pubmed-article:7814893 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7814893 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7814893 | pubmed:pagination | 922-7 | lld:pubmed |
| pubmed-article:7814893 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:meshHeading | pubmed-meshheading:7814893-... | lld:pubmed |
| pubmed-article:7814893 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7814893 | pubmed:articleTitle | Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. | lld:pubmed |
| pubmed-article:7814893 | pubmed:affiliation | Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892. | lld:pubmed |
| pubmed-article:7814893 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7814893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7814893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7814893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7814893 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7814893 | lld:pubmed |
